Single-Center Experience with Axicabtagene-Ciloleucel (Axi-cel) and Tisagenlecleucel (Tisa-cel) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Comparable Response Rates and Manageable Toxicity

被引：5
|
作者：
Buecklein, Veit
Blumenberg, Viktoria
Ackermann, Josephine
Schmidt, Christian
Rejeski, Kai
Mueller, Niklas
Reischer, Anna
von Baumgarten, Louisa
Schoeberl, Florian
Humpe, Andreas
von Bergwelt, Michael
Subklewe, Marion
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142932
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A Propensity Score-Matched Comparison of Axi-Cel and Tisa-Cel for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Real-Life: A Lysa Study from the Descar-T Registry
    Bachy, Emmanuel
    Le Gouill, Steven
    Di Blasi, Roberta
    Sesques, Pierre
    Cartron, Guillaume
    Beauvais, David
    Roulin, Louise
    Gros, Francois Xavier
    Sylvain, Choquet
    Bories, Pierre
    Rubio, Marie Therese
    Casasnovas, Rene-Olivier
    Bay, Jacques-Olivier
    Mohty, Mohamad
    Joris, Magalie
    Gastinne, Thomas
    Tudesq, Jean Jacques
    Chaillol, Isabelle
    Broussais, Florence
    Thieblemont, Catherine
    Houot, Roch
    Morschhauser, Franck
    BLOOD, 2021, 138
  • [22] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
    Topp, Max S.
    van Meerten, Tom
    Hout, Roch
    Minnema, Monique C.
    Milpied, Noel
    Lugtenburg, Pieternella J.
    Thieblemont, Catherine
    Wermke, Martin
    Song, Kevin W.
    Avivi, Irit
    Kuruvilla, John
    Duehrsen, Ulrich
    Chu, Rong
    Zheng, Lianqing
    Plaks, Vicki
    Kerber, Anne
    Kersten, Marie Jose
    MOLECULAR THERAPY, 2020, 28 (04) : 577 - 577
  • [23] AN UPDATED TWO-YEAR SURVIVAL ANALYSIS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (R/R-LBCL)
    Diakite, I
    Lin, V. W.
    Klijn, S.
    Navale, L.
    Purdum, A. G.
    Fenwick, E.
    Botteman, M.
    van Hout, B.
    VALUE IN HEALTH, 2019, 22 : S41 - S41
  • [24] Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma
    Filosto, Simone
    Vardhanabhuti, Saran
    Canales, Miguel
    Poire, Xavier
    Lekakis, Lazaros J.
    de Vos, Sven
    Portell, Craig A.
    Wang, Zixing
    To, Christina
    Cheng, Paul
    Chou, Justin
    Bot, Adrian
    Shen, Rhine
    Westin, Jason R.
    CANCER RESEARCH, 2022, 82 (12)
  • [25] Budget Impact Model of Axicabtagene Ciloleucel (Axi-cel) in a US Population of Patients with Relapsed or Refractory Large B-Cell Lymphoma (R/R-LBCL)
    Hathway, Joanne
    Purdum, Anna
    Lin, Vincent W.
    Cyr, Philip
    Westin, Jason
    Jensen, Ivar
    BONE MARROW TRANSPLANTATION, 2018, 53 : 878 - 879
  • [26] Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma
    Oluwole, Olalekan O.
    Chen, Jenny M. H.
    Chan, Keith
    Patel, Anik R.
    Jansen, Jeroen P.
    Keeping, Sam
    Zheng, Yan
    Snider, Julia T.
    Locke, Frederick L.
    LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3052 - 3062
  • [27] COST-EFFECTIVENESS OF AXICABTAGENE CILOLEUCEL (AXI-CEL) VS STANDARD OF CARE FOR ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN SWEDEN, NORWAY, FINLAND, AND DENMARK
    Karampampa, K.
    Stene, E.
    Axelsen, F.
    Lyngaa, R.
    Vadgama, S.
    Jerkeman, M.
    Wilen-Koort, A.
    Wallace, K.
    VALUE IN HEALTH, 2020, 23 : S687 - S687
  • [28] Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
    Bharadwaj, Sushma
    Lau, Eric
    Goyal, Anmol
    Hamilton, Mark P.
    Srinagesh, Hrishikesh
    Jensen, Alexandria
    Syal, Shriya
    Mallampet, Jayasindhu
    Latchford, Theresa
    Sahaf, Bita
    Weng, Wen-Kai
    Smith, Melody
    Maecker, Holden T.
    Frank, Matthew J.
    Miklos, David B.
    Dahiya, Saurabh
    BLOOD, 2023, 142
  • [29] Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
    Nastoupil, Loretta J.
    Jain, Michael D.
    Spiegel, Jay Y.
    Ghobadi, Armin
    Lin, Yi
    Dahiya, Saurabh
    Lunning, Matthew A.
    Lekakis, Lazaros J.
    Reagan, Patrick M.
    Oluwole, Olalekan O.
    McGuirk, Joseph P.
    Deol, Abhinav
    Sehgal, Alison R.
    Goy, Andre
    Hill, Brian T.
    Andreadis, Charalambos
    Munoz, Javier
    Westin, Jason R.
    Chavez, Julio C.
    Cashen, Amanda F.
    Bennani, Nora N.
    Rapoport, Aaron P.
    Vose, Julie M.
    Miklos, David B.
    Neelapu, Sattva S.
    Locke, Frederick L.
    BLOOD, 2018, 132
  • [30] Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
    Ahmed, Sairah
    Furqan, Fateeha
    Strati, Paolo
    Westin, Jason
    Fayad, Luis
    Hagemeister, Frederick B.
    Lee, Hun Ju
    Iyer, Swaminathan Padmanabhan
    Nair, Ranjit
    Nastoupil, Loretta J.
    Parmar, Simrit
    Rodriguez, Maria Alma
    Samaniego, Felipe
    Steiner, Raphael
    Wang, Michael
    Pinnix, Chelsea Camille
    Flowers, Christopher
    Horowitz, Sandra B.
    Hawkins, Misha
    Neelapu, Sattva Swarup
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345